EDMONTON, ALBERTA--(CCNMatthews - Nov. 30, 2004) - CV Technologies Inc. (TSX VENTURE:CVQ) (CVT) today announced that it is launching a pre-clinical study to investigate the effects of CVT-E002 in treating immune deficiency related cancers as part of its ongoing strategy to develop natural therapeuticals for disease prevention and health maintenance.
The pre-clinical study, to be conducted in collaboration with McGill University in Montreal, Quebec will investigate the potential of CVT-E002 to ameliorate leukemia caused by viral infection. The study will also provide further detailed understanding of the effect of CVT-E002 on cancer killing mechanisms in relation to the immune system.
President, CEO & Chief Scientific Officer, Dr. Jacqueline Shan said, "This study highlights the significant potential of CVT-E002 for prevention and treatment of immune deficiency related cancers. The decision to proceed with the study was based largely on promising preliminary results."
The National Research Council (NRC) - Industrial Research Assistance Program (IRAP) has providing funding for the project. Dr. Shan said, "The involvement of the NRC-IRAP in contributing to this study demonstrates their confidence in the scientific potential of this project."
While CVT-E002 is in the developmental phase for immune-related cancers, it has a patent for formulation and many preventative, immune-related, therapeutic applications such as cold and flu infections, hepatitis, HIV, and primary and supportive cancer therapy.
Dr. Shan said, "CVT-E002 is the potent active ingredient in COLD-fX, which has an excellent safety profile. The efficacy of CVT-E002 for other viral-associated pathologies makes it an ideal candidate for cancer prevention and therapy." Current therapies for many cancers are often coupled with severe debilitating side effects. CVT-E002 is an attractive potential alternative either as an adjuvant or primary therapy for cancer because numerous clinical trials have demonstrated it is safe and well-tolerated. CVT-E002 specifically targets non-specific, cancer killing immune cells, such as Natural Killer (NK) cells. This NRC-funded study will provide laboratory efficacy and dosage information for possible future clinical studies in cancer patients.
ABOUT CV TECHNOLOGIES INC.
CV Technologies is a biotechnology company founded in 1992. It aims to become a global leader in the development and commercialization of safe and effective, evidence based, natural therapeutics for disease prevention and health maintenance. CVT's lead product, COLD-fX(R), strengthens the immune system and is widely used as a leading anti-cold, anti-flu, non-prescription drug. COLD-fX(R) is patented and its unique mechanism of action is developed and standardized according to the Company's ChemBioPrint technology, a patented process that precisely identifies the chemical profile and biological activity of patented multi-active components-based natural therapeutics. This is a combination of chemical and pharmacological fingerprinting that ensures each batch of products delivers verifiable and provable health benefits, and is both safe and consistent with previous batches.
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.
- 30 -